Optic Nerve Drusen: Buried "Pseudopapilledema" Explained

Common, Usually Benign, But Must Be Distinguished from True Papilledema

Optic nerve head drusen (ONHD) are acellular, calcified deposits within the optic nerve head. They mimic papilledema (pseudopapilledema) but are usually benign.

Epidemiology & Etiology

  • Prevalence: 0.5–2% (autopsy); clinical detection lower.
  • Autosomal dominant with incomplete penetrance.
  • Mechanism: axoplasmic stasis at lamina cribrosa → mitochondrial accumulation → calcification.
  • Associated: retinitis pigmentosa, Usher syndrome, Alagille, angioid streaks.

Clinical Presentation

  • Often asymptomatic; incidental finding.
  • Visible drusen: "lumpy-bumpy" disc, autofluorescence (calcific), nasal disc margin.
  • Buried drusen: elevated disc, blurred margins, no spontaneous venous pulsation — mimics papilledema.
  • Visual field defects: arcuate scotomas, nasal step, enlarged blind spot (10–15%).
  • Rare: AION-like sudden loss (vascular compression), choroidal neovascularization.

Diagnostic Differentiation: Drusen vs. True Papilledema

FeatureDrusenPapilledema
OnsetChronic, stableAcute/subacute
SymptomsUsually noneHeadache, nausea, transient visual obscurations
Disc appearanceIrregular, refractile bodies; vessels not obscuredSmooth elevation, blurred margins, vessels obscured
Spontaneous venous pulsationOften absentAbsent
Autofluorescence / OCTHyperautofluorescent foci; lumpy RNFLSmooth RNFL thickening
B-scan ultrasoundHigh reflectivity (calcification)Normal / optic nerve sheath dilation
Systemic signsNoneIIH: obesity, tinnitus, VI palsy

Monitoring & Management

  • Baseline: VF (Humphrey 24-2), OCT RNFL, disc photos, autofluorescence.
  • Annual monitoring (VF, OCT).
  • IOP check (higher NTG risk).
  • Visual field defect progression → consider IOP lowering even if normal.
  • No prophylaxis for CNV; treat if develops (anti-VEGF).
  • Genetic counseling if syndromic features.

Patient Education

  • Not a tumor; not progressive in most.
  • Carry diagnosis card (avoids unnecessary ER workup for "papilledema").
  • Inform all eye providers.
  • Sports: no restriction unless visual field defect affects safety.

Bottom Line

ONHD is a common, usually benign congenital anomaly. Key task: distinguish from true papilledema. Lifelong monitoring for visual field loss and NTG risk. Reassure, don't alarm.

Eye & Vision Disorders - Related Articles